Ronald L Gibson

Summary

Affiliation: University of Washington
Country: USA

Publications

  1. ncbi request reprint Duration of treatment effect after tobramycin solution for inhalation in young children with cystic fibrosis
    Ronald L Gibson
    Department of Pediatrics, University of Washington Children s Hospital and Regional Medical Center, Seattle, WA 98105 0371, USA
    Pediatr Pulmonol 42:610-23. 2007
  2. ncbi request reprint Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis
    Ronald L Gibson
    Department of Pediatrics, Children s Hospital and Regional Medical Center University of Washington, Seattle, Washington 98105 0371, USA
    Am J Respir Crit Care Med 167:841-9. 2003
  3. ncbi request reprint Microbiology, safety, and pharmacokinetics of aztreonam lysinate for inhalation in patients with cystic fibrosis
    Ronald L Gibson
    Department of Pediatrics, University of Washington, Children s Hospital and Regional Medical Center, Seattle, Washington 98105 0371, USA
    Pediatr Pulmonol 41:656-65. 2006
  4. pmc Impact of Pseudomonas and Staphylococcus infection on inflammation and clinical status in young children with cystic fibrosis
    Scott D Sagel
    Department of Pediatrics, The Children s Hospital and University of Colorado Health Sciences Center, Aurora, CO 80045, USA
    J Pediatr 154:183-8. 2009
  5. pmc Early anti-pseudomonal acquisition in young patients with cystic fibrosis: rationale and design of the EPIC clinical trial and observational study'
    Miriam M Treggiari
    Department of Anesthesiology and Pain Medicine, University of Washington School of Medicine, Seattle, WA 98104, USA
    Contemp Clin Trials 30:256-68. 2009
  6. pmc Randomized trial of biofilm testing to select antibiotics for cystic fibrosis airway infection
    Samuel M Moskowitz
    Department of Pediatrics, Massachusetts General Hospital, Boston, Massachusetts Department of Pediatrics, University of Washington School of Medicine, Seattle, Washington Seattle Children s Hospital, Seattle, Washington
    Pediatr Pulmonol 46:184-92. 2011
  7. doi request reprint Baseline characteristics and factors associated with nutritional and pulmonary status at enrollment in the cystic fibrosis EPIC observational cohort
    Margaret Rosenfeld
    Department of Pediatrics, Seattle Children s Hospital and University of Washington, Seattle, Washington, USA
    Pediatr Pulmonol 45:934-44. 2010
  8. ncbi request reprint Randomized, double-blind, placebo-controlled, dose-escalating study of aerosolized interferon gamma-1b in patients with mild to moderate cystic fibrosis lung disease
    Richard B Moss
    Department of Pediatrics, Stanford University Medical Center, Palo Alto, California 94304 5786, USA
    Pediatr Pulmonol 39:209-18. 2005
  9. pmc Initial Pseudomonas aeruginosa treatment failure is associated with exacerbations in cystic fibrosis
    Nicole Mayer-Hamblett
    Department of Pediatrics, University of Washington, Seattle, Washington Seattle Children s Hospital, Seattle, Washington, USA
    Pediatr Pulmonol 47:125-34. 2012
  10. ncbi request reprint Inflammatory and microbiologic markers in induced sputum after intravenous antibiotics in cystic fibrosis
    Claudia L Ordonez
    Department of Pediatrics, Harvard Medical School, Boston, MA 02215, USA
    Am J Respir Crit Care Med 168:1471-5. 2003

Detail Information

Publications31

  1. ncbi request reprint Duration of treatment effect after tobramycin solution for inhalation in young children with cystic fibrosis
    Ronald L Gibson
    Department of Pediatrics, University of Washington Children s Hospital and Regional Medical Center, Seattle, WA 98105 0371, USA
    Pediatr Pulmonol 42:610-23. 2007
    ..Early intervention strategies include tobramycin solution for inhalation (TSI), which can eradicate lower airway Pa from cultures obtained at the end of 28 days of treatment in young children...
  2. ncbi request reprint Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis
    Ronald L Gibson
    Department of Pediatrics, Children s Hospital and Regional Medical Center University of Washington, Seattle, Washington 98105 0371, USA
    Am J Respir Crit Care Med 167:841-9. 2003
    ..We conclude that 28 days of tobramycin solution for inhalation of 300 mg twice daily is safe and effective for significant reduction of lower airway Pa density in young children with cystic fibrosis...
  3. ncbi request reprint Microbiology, safety, and pharmacokinetics of aztreonam lysinate for inhalation in patients with cystic fibrosis
    Ronald L Gibson
    Department of Pediatrics, University of Washington, Children s Hospital and Regional Medical Center, Seattle, Washington 98105 0371, USA
    Pediatr Pulmonol 41:656-65. 2006
    ..Aztreonam lysinate for inhalation (AI) is a novel monobactam formulation being investigated for pulmonary Pseudomonas aeruginosa infections in patients with cystic fibrosis (CF)...
  4. pmc Impact of Pseudomonas and Staphylococcus infection on inflammation and clinical status in young children with cystic fibrosis
    Scott D Sagel
    Department of Pediatrics, The Children s Hospital and University of Colorado Health Sciences Center, Aurora, CO 80045, USA
    J Pediatr 154:183-8. 2009
    ..To assess the effects of Pseudomonas aeruginosa and Staphylococcus aureus infection on lower airway inflammation and clinical status in young children with cystic fibrosis (CF)...
  5. pmc Early anti-pseudomonal acquisition in young patients with cystic fibrosis: rationale and design of the EPIC clinical trial and observational study'
    Miriam M Treggiari
    Department of Anesthesiology and Pain Medicine, University of Washington School of Medicine, Seattle, WA 98104, USA
    Contemp Clin Trials 30:256-68. 2009
    ..Risk factors for and clinical impact of early Pa infection in young CF patients are less well understood...
  6. pmc Randomized trial of biofilm testing to select antibiotics for cystic fibrosis airway infection
    Samuel M Moskowitz
    Department of Pediatrics, Massachusetts General Hospital, Boston, Massachusetts Department of Pediatrics, University of Washington School of Medicine, Seattle, Washington Seattle Children s Hospital, Seattle, Washington
    Pediatr Pulmonol 46:184-92. 2011
    ..In cystic fibrosis (CF), conventional antibiotic susceptibility results correlate poorly with clinical outcomes. We hypothesized that biofilm testing would more accurately reflect the susceptibilities of bacteria infecting CF airways...
  7. doi request reprint Baseline characteristics and factors associated with nutritional and pulmonary status at enrollment in the cystic fibrosis EPIC observational cohort
    Margaret Rosenfeld
    Department of Pediatrics, Seattle Children s Hospital and University of Washington, Seattle, Washington, USA
    Pediatr Pulmonol 45:934-44. 2010
    ..The EPIC Observational Study is an ongoing prospective cohort study investigating risk factors for and clinical outcomes associated with early Pseudomonas aeruginosa (Pa) acquisition in young children with cystic fibrosis (CF)...
  8. ncbi request reprint Randomized, double-blind, placebo-controlled, dose-escalating study of aerosolized interferon gamma-1b in patients with mild to moderate cystic fibrosis lung disease
    Richard B Moss
    Department of Pediatrics, Stanford University Medical Center, Palo Alto, California 94304 5786, USA
    Pediatr Pulmonol 39:209-18. 2005
    ..Aerosolized IFN-gamma1b did not improve pulmonary function, reduce sputum bacterial density, or affect inflammatory sputum markers in patients with mild-moderate lung disease...
  9. pmc Initial Pseudomonas aeruginosa treatment failure is associated with exacerbations in cystic fibrosis
    Nicole Mayer-Hamblett
    Department of Pediatrics, University of Washington, Seattle, Washington Seattle Children s Hospital, Seattle, Washington, USA
    Pediatr Pulmonol 47:125-34. 2012
    ..The risk of pulmonary exacerbation following Pseudomonas aeruginosa (Pa) acquisition in children with cystic fibrosis (CF) is unknown...
  10. ncbi request reprint Inflammatory and microbiologic markers in induced sputum after intravenous antibiotics in cystic fibrosis
    Claudia L Ordonez
    Department of Pediatrics, Harvard Medical School, Boston, MA 02215, USA
    Am J Respir Crit Care Med 168:1471-5. 2003
    ..Seven of 127 (6%) sputum induction procedures showed a decrease in FEV1 of 20% or more. We conclude that markers in induced sputum may be useful, noninvasive outcome measures to assess response to therapies in cystic fibrosis studies...
  11. doi request reprint Risk factors for age at initial Pseudomonas acquisition in the cystic fibrosis epic observational cohort
    Margaret Rosenfeld
    Department of Pediatrics, Seattle Children s Hospital and University of Washington, Seattle, WA 98105, USA
    J Cyst Fibros 11:446-53. 2012
    ..We aimed to identify such risk factors in order to inform prevention strategies and identify high-risk populations...
  12. ncbi request reprint A phase 2 study of aztreonam lysine for inhalation to treat patients with cystic fibrosis and Pseudomonas aeruginosa infection
    George Z Retsch-Bogart
    Department of Pediatrics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599 7220, USA
    Pediatr Pulmonol 43:47-58. 2008
    ..Aztreonam lysine for inhalation (AZLI) is being developed for treatment of CF patients with Pseudomonas aeruginosa airway infection...
  13. doi request reprint Standard care versus protocol based therapy for new onset Pseudomonas aeruginosa in cystic fibrosis
    Nicole Mayer-Hamblett
    Department of Pediatrics, University of Washington, Seattle, Washington Seattle Children s Hospital, Seattle, Washington
    Pediatr Pulmonol 48:943-53. 2013
    ....
  14. pmc Efficacy and safety of inhaled aztreonam lysine for airway pseudomonas in cystic fibrosis
    George Z Retsch-Bogart
    Department of Pediatrics, University of North Carolina, Chapel Hill, NC 27599 7217, USA
    Chest 135:1223-32. 2009
    ..We assessed the short-term efficacy and safety of aztreonam lysine for inhalation (AZLI [an aerosolized monobactam antibiotic]) in patients with cystic fibrosis (CF) and Pseudomonas aeruginosa (PA) airway infection...
  15. pmc Clinical practice and genetic counseling for cystic fibrosis and CFTR-related disorders
    Samuel M Moskowitz
    Department of Pediatrics, University of Washington School of Medicine, Seattle, Washington 98195 7740, USA
    Genet Med 10:851-68. 2008
    ..Widespread implementation of newborn screening programs among populations with significant cystic fibrosis mutation carrier frequencies is expected to result in increasing demands on genetic counseling resources...
  16. ncbi request reprint Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis
    Julia Emerson
    Division of Pulmonary Medicine, Department of Pediatrics, University of Washington, Seattle, USA
    Pediatr Pulmonol 34:91-100. 2002
    ..These findings confirm reports from previous smaller studies of outcomes among young children with CF, and highlight the potential to decrease the morbidity and mortality of young patients with CF through early intervention...
  17. doi request reprint Respiratory viruses in children with cystic fibrosis: viral detection and clinical findings
    Jane L Burns
    Department of Pediatrics, Division of Infectious Diseases, University of Washington and Seattle Children s Hospital, USA
    Influenza Other Respir Viruses 6:218-23. 2012
    ..In addition, associations between viral detection and respiratory symptoms are not well described...
  18. pmc Selection for Staphylococcus aureus small-colony variants due to growth in the presence of Pseudomonas aeruginosa
    Lucas R Hoffman
    Department of Pediatrics, University of Washington, Seattle, WA 98195, USA
    Proc Natl Acad Sci U S A 103:19890-5. 2006
    ....
  19. ncbi request reprint Use of Pseudomonas biofilm susceptibilities to assign simulated antibiotic regimens for cystic fibrosis airway infection
    Samuel M Moskowitz
    Department of Pediatrics, University of Washington School of Medicine, Seattle, WA, USA
    J Antimicrob Chemother 56:879-86. 2005
    ..As a prelude to a clinical trial of biofilm susceptibility testing in CF, simulated antibiotic regimens based on either biofilm or conventional susceptibility testing of CF patient isolates were compared...
  20. doi request reprint Staphylococcus aureus small-colony variants are independently associated with worse lung disease in children with cystic fibrosis
    Daniel J Wolter
    Departments of Pediatrics, University of Washington, Seattle, WA 98105, USA
    Clin Infect Dis 57:384-91. 2013
    ..We sought to determine the prevalence, clinical significance, and likely mechanisms of selection of S. aureus SCVs among a US cohort of children with CF...
  21. doi request reprint Feasibility of using pedometers to measure daily step counts in cystic fibrosis and an assessment of its responsiveness to changes in health state
    Bradley S Quon
    Division of Pulmonary and Critical Care Medicine, Department of Medicine, University of Washington Medical Center, Seattle, WA 98195, USA
    J Cyst Fibros 11:216-22. 2012
    ..We evaluated the feasibility of using pedometers to measure physical activity in adolescents and adults with cystic fibrosis (CF) and assessed the responsiveness of its measurement to changes in health state...
  22. ncbi request reprint Pseudomonas acquisition in young patients with cystic fibrosis: pathophysiology, diagnosis, and management
    Margaret Rosenfeld
    Department of Pediatrics, University of Washington, Seattle, USA
    Curr Opin Pulm Med 9:492-7. 2003
    ..To summarize the pathophysiology of, risk factors for, and outcomes of early Pseudomonas aeruginosa (Pa) infection in CF; to review the results of trials of early intervention and to describe treatment options for early Pa infection...
  23. ncbi request reprint Pathophysiology and management of pulmonary infections in cystic fibrosis
    Ronald L Gibson
    Department of Pediatrics, University of Washington School of Medicine, Children s Hospital, Seattle, WA 98125, USA
    Am J Respir Crit Care Med 168:918-51. 2003
    ..In addition, the article discusses infection control policies, therapies to optimize airway clearance and reduce inflammation, and potential future therapies...
  24. ncbi request reprint Prevalence of neutralizing antibodies against adeno-associated virus (AAV) types 2, 5, and 6 in cystic fibrosis and normal populations: Implications for gene therapy using AAV vectors
    Christine L Halbert
    Division of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    Hum Gene Ther 17:440-7. 2006
    ..AAV5-positive sera were lower both in titers and rates than those seen for AAV6. The results indicate that AAV type 2, 5 or 6 exposure is low in CF and control populations and even lower in CF children...
  25. ncbi request reprint Pharmacogenomic testing to prevent aminoglycoside-induced hearing loss in cystic fibrosis patients: potential impact on clinical, patient, and economic outcomes
    David L Veenstra
    Institute for Public Health Genetics, Department of Pharmacy, University of Washington, Seattle, Washington 98195, USA
    Genet Med 9:695-704. 2007
    ..Although the A1555G variant is very rare, it seems to confer a high risk of severe hearing loss in patients exposed to aminoglycosides...
  26. pmc Exome sequencing of extreme phenotypes identifies DCTN4 as a modifier of chronic Pseudomonas aeruginosa infection in cystic fibrosis
    Mary J Emond
    Department of Biostatistics, University of Washington, Seattle, Washington, USA
    Nat Genet 44:886-9. 2012
    ..aeruginosa airway infection, chronic P. aeruginosa infection and mucoid P. aeruginosa in individuals with cystic fibrosis...
  27. ncbi request reprint The prevalence of ibuprofen-sensitive asthma in children: a randomized controlled bronchoprovocation challenge study
    Jason S Debley
    Department of Pediatrics, Division of Pulmonary Medicine, University of Washington, Seattle, Washington 98105, USA
    J Pediatr 147:233-8. 2005
    ..To determine the prevalence of ibuprofen-sensitive asthma in school-aged children with mild or moderate persistent asthma...
  28. ncbi request reprint Analysis of sequential aliquots of hypertonic saline solution-induced sputum from clinically stable patients with cystic fibrosis
    Moira L Aitken
    Department of Medicine, Division of Pulmonary and Critical Care, University of Washington, Seattle 98195, USA
    Chest 123:792-9. 2003
    ..The hypothesis was that the duration of SI collection would quantitatively and qualitatively alter the content of the induced sputum...
  29. ncbi request reprint Cystic fibrosis lung disease: genetic influences, microbial interactions, and radiological assessment
    Samuel M Moskowitz
    Department of Pediatrics, University of Washington School of Medicine and Children s Hospital and Regional Medical Center, Seattle, WA 98105, USA
    Pediatr Radiol 35:739-57. 2005
    ..In this review, perspectives on the genetics and microbiology of CF provide a context for understanding the increasing importance of HRCT and other imaging techniques in assessing CF therapies...
  30. ncbi request reprint Lipoid pneumonia due to Mexican folk remedies: cultural barriers to diagnosis
    Lucas R Hoffman
    Department of Pediatrics and Radiology, University of Washington School of Medicine, Seattle, WA, USA
    Arch Pediatr Adolesc Med 159:1043-8. 2005
    ..Lipoid pneumonia is a known complication of such practices in Mexico, India, Saudi Arabia, and other countries...
  31. ncbi request reprint Oral corticosteroid therapy in cystic fibrosis patients hospitalized for pulmonary exacerbation: a pilot study
    Mark Dovey
    Section of Pediatric Pulmonology and Allergy, St Christopher s Hospital For Children, Philadelphia, PA, USA
    Chest 132:1212-8. 2007
    ..We hypothesized that adding 5 days of prednisone to standard therapy for acute pulmonary exacerbations in patients with cystic fibrosis (CF) would result in a more rapid and greater increase in lung function...